

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Ifu

Applicant: Keith V. Wood et al.

Title: COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS

Docket No.: 341.020US1

Filed: January 30, 2004

Examiner: Unknown



Serial No.: 10/768,976

Due Date: N/A

Group Art Unit: 1645

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


We are transmitting herewith the following attached items (as indicated with an "X"):

☒ A return postcard.


☒ An Information Disclosure Statement (2 pgs.), Form 1449 (1 pg.), and copies of 23 cited documents.


If not provided for in a separate paper filed herewith, Please consider this a **PETITION FOR EXTENSION OF TIME** for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
Customer Number 21186

By: 
Atty: Janet E. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 4th day of August, 2004.


Name


Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
(GENERAL)



Serial No. 10/768,976

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant:	Keith V. Wood et al.	Examiner:	Unknown
Serial No.:	10/768,976	Group Art Unit:	1645
Filed:	January 30, 2004	Docket:	341.020US1
Title:	COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS		

INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.



INFORMATION DISCLOSURE STATEMENT

Serial No : 10/768,976

Filing Date: January 30, 2004

Title: COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS

Page 2
Dkt: 341.020US1

The present application is either a U.S. national patent application filed after June 30, 2003 or an international application that entered the national stage under 35 U.S.C. § 371 after June 30, 2003. Thus, Applicant believes that the U.S. Patent & Trademark Office has waived the requirement under 37 C.F.R. 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication. The waiver is provided in a pre-OG notice from the U.S. Patent & Trademark Office entitled "Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003" and dated July 11, 2003. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

KEITH V. WOOD ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date

August 4, 2004

By

Janet E. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 4th day of August, 2004.

Name

Indef. Dent

Signature

[Signature]



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/768,976
Filing Date	January 30, 2004
First Named Inventor	Wood, Keith
Group Art Unit	1645
Examiner Name	

Sheet 1 of 2

Attorney Docket No: 341.020US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
	US-2002/0137171	09/26/2002	Short et al.	435	196	11/30/2001
	US-5,372,944	12/13/1994	Swanson, P.	435	252.1	10/14/1993
	US-5,576,424	11/19/1996	Mao et al.	536	17.9	11/08/1994

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
	WO-02/083937	10/24/2002	Kiddle, S.	C12Q	1/48	
	WO-02/28841A2	04/11/2002	Haugland, R., et al.	C07D	239/91	
	WO-02/057411A2	07/25/2002	Short, J., et al.	C12N		
	WO-02/068583A2	09/06/2002	Short, J. M.	C12N	9/14	
	WO-98/36080	08/20/1998	Affholter, J., et al.	C12N	15/55	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ADACHI, H. , et al., "Site-directed mutants, at position 166, of RTEM-1 beta-lactamase that form a stable acyl-enzyme intermediate with penicillin", <u>J Biol Chem.</u> , 266(5), (Feb 1991), pp. 3186-91	
		ARAVIND, L. , "An evolutionary classification of the metallo-beta-lactamase fold proteins", <u>In Silico Biol.</u> , 1(2), (1999), pp. 69-91	
		BIER, C , "Covalys - one tag does it all", <u>Bio World</u> , (2003), pp. 46-47	
		BOSMA, et al., "Biodegradation of 1,2,3-trichloropropane through directed evolution and heterologous expression of a haloalkane dehalogenase gene", <u>Appl Environ Microbiol.</u> (Jul 2002), pp. 3582-7	
		CHALOUPOVA, R , "Modification of activity and specificity of haloalkane dehalogenase from <i>Sphingomonas paucimobilis</i> UT26 by engineering of its entrance tunnel", <u>J Biol Chem.</u> , (Dec 26 2003), pp. 52622-8	
		CHEN, C. , "Relocation of the catalytic carboxylate group in class A beta-lactamase: the structure and function of the mutant enzyme Glu166-->Gln:Asn170-->Asp.", <u>Protein Eng.</u> , 12(7), (July 1999), pp. 573-9	
		FRANKEN, S. , et al., "Crystal structure of haloalkane dehalogenase: an enzyme to detoxify halogenated alkanes", <u>EMBO J.</u> , 10(6), (June 1991), pp. 1297-302	
		GRAY, K , et al., "Rapid evolution of reversible denaturation and elevated melting temperature in a microbial haloalkane dehalogenase", <u>Adv. Synth. Catal.</u> , (2001), pp. 607-17	
		GRIFFIN, B. A., et al., "Specific covalent labeling of recombinant protein molecules inside live cells", <u>Science</u> , 281(5374), (July 1998), pp. 269-72	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/768,976
Filing Date	January 30, 2004
First Named Inventor	Wood, Keith
Group Art Unit	1645
Examiner Name	

Sheet 2 of 2

Attorney Docket No: 341.020US1

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KEPPLER, A. , et al., "A general method for the covalent labeling of fusion proteins with small molecules in vivo", <u>Nature Biotechnology</u> , 21, (January 2003), pp. 86-9	
		KROOSHOF, G. , et al., "Repositioning the catalytic triad aspartic acid of haloalkane dehalogenase: effects on stability, kinetics, and structure", <u>Biochemistry</u> , 36(31), (August 1997), pp. 9571-80	
		KULAKOVA, A. , "The plasmid-located haloalkane dehalogenase gene from <i>Rhodococcus rhodochrous</i> NCIMB 13064", <u>Microbiology</u> , 143 (Pt 1), (January 1997), pp. 109-15	
		PIETERS, R. , et al., "Design and synthesis of reagents for phage display screening of dehalogenases", <u>Bioorg Med Chem Lett.</u> , 9(2), (January 1999), pp. 161-6	
		PRIES, F. , et al., "Histidine 289 is essential for hydrolysis of the alkyl-enzyme intermediate of haloalkane dehalogenase", <u>J Biol Chem.</u> , 270(18), (May 1995), pp. 10405-11	
		STROFFEKOVA, K. , et al., "The protein-labeling reagent FLASH-EDT2 binds not only to CCXXCC motifs but also non-specifically to endogenous cysteine-rich proteins", <u>Pflugers Arch.</u> , 442(6), (September 2001), pp. 859-66	
		WADA, K. , et al., "Codon usage tabulated from the GenBank genetic sequence data", <u>Nucleic Acids Res.</u> , (May 1992), pp. 2111-8	
		WINBERG, J. , "The catalytic triad in short-chain dehydrogenases", <u>Dept. of Biochemistry, Institute of Medical Biology, University of Tromsø</u> , Abstract, (November 2002), 2 pgs.	
		ZAWADZKE, L. , "Elimination of the hydrolytic water molecule in a class A beta-lactamase mutant: crystal structure and kinetics", <u>Biochemistry</u> , (December 1996), pp. 16475-82	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached